Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia

Despite the success of imatinib mesylate (IM) in the early chronic phase of chronic myeloid leukemia (CML), patients are resistant to IM and other kinase inhibitors in the later stages of CML. Our findings indicate that inhibition of Janus kinase 2 (Jak2) in Bcr–Abl+ cells overcomes IM resistance al...

Descripción completa

Detalles Bibliográficos
Autores principales: Samanta, A, Perazzona, B, Chakraborty, S, Sun, X, Modi, H, Bhatia, R, Priebe, W, Arlinghaus, R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072513/
https://www.ncbi.nlm.nih.gov/pubmed/21183952
http://dx.doi.org/10.1038/leu.2010.287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072513/
https://www.ncbi.nlm.nih.gov/pubmed/21183952
http://dx.doi.org/10.1038/leu.2010.287

Ejemplares similares